Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Myriad Genetics (MYGN) over the last 17 years, with Q3 2025 value amounting to $12.2 million.

  • Myriad Genetics' Share-based Compensation fell 161.29% to $12.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $43.3 million, marking a year-over-year decrease of 1217.04%. This contributed to the annual value of $49.8 million for FY2024, which is 2235.87% up from last year.
  • Latest data reveals that Myriad Genetics reported Share-based Compensation of $12.2 million as of Q3 2025, which was down 161.29% from $10.7 million recorded in Q2 2025.
  • Myriad Genetics' 5-year Share-based Compensation high stood at $14.5 million for Q2 2024, and its period low was $7.5 million during Q1 2023.
  • For the 5-year period, Myriad Genetics' Share-based Compensation averaged around $10.4 million, with its median value being $10.4 million (2022).
  • Per our database at Business Quant, Myriad Genetics' Share-based Compensation tumbled by 4362.42% in 2021 and then skyrocketed by 6000.0% in 2024.
  • Quarter analysis of 5 years shows Myriad Genetics' Share-based Compensation stood at $8.4 million in 2021, then dropped by 2.38% to $8.2 million in 2022, then rose by 26.83% to $10.4 million in 2023, then grew by 4.81% to $10.9 million in 2024, then increased by 11.93% to $12.2 million in 2025.
  • Its last three reported values are $12.2 million in Q3 2025, $10.7 million for Q2 2025, and $9.5 million during Q1 2025.